Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.080 +0.080 (+4.00%)

Official Closing Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	7,174,083
Open	1.970
Bid (Size)	2.100 (2,500)
Ask (Size)	2.110 (3,100)
Prev. Close	2.000
Today's Range	1.950 - 2.130
52wk Range	1.830 - 5.430
Shares Outstanding	391,156,513
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

November 13, 2025

From ImmunityBio, Inc.

Via Business Wire

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

November 04, 2025

From ImmunityBio, Inc.

Via Business Wire

Performance

YTD	-19.1%	-19.1%
1 Month	-19.4%	-19.4%
3 Month	-18.4%	-18.4%
6 Month	-26.8%	-26.8%
1 Year	-57.3%	-57.3%

More News

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks ↗

October 22, 2025

Via Benzinga

ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals ↗

September 17, 2025

Via Stocktwits

Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗

September 17, 2025

Via MarketBeat

Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts ↗

September 12, 2025

Via Stocktwits

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

September 08, 2025

From ImmunityBio, Inc.

Via Business Wire

What's Going On With ImmunityBio Shares Tuesday? ↗

August 26, 2025

Via Benzinga

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

August 26, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

August 19, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

August 13, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

August 11, 2025

From ImmunityBio, Inc.

Via Business Wire

IBRX Sales Soar 2,540% ↗

August 05, 2025

Via The Motley Fool

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

August 05, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

July 25, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

July 25, 2025

From ImmunityBio, Inc.

Via Business Wire

LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper ↗

July 22, 2025

Via Benzinga

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

July 09, 2025

Via Investor Brand Network

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

July 09, 2025

Via FinancialNewsMedia

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

July 07, 2025

From ImmunityBio, Inc.

Via Business Wire

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

June 03, 2025

From ImmunityBio, Inc.

Via Business Wire

Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday ↗

June 02, 2025

Via Benzinga

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

June 02, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

May 27, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The Upside ↗

May 18, 2025

Via Stocktwits

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?

Yes, ImmunityBio, Inc. - Common Stock is publicly traded.

What exchange does ImmunityBio, Inc. - Common Stock trade on?

ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ImmunityBio, Inc. - Common Stock?

The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market

What is the current price of ImmunityBio, Inc. - Common Stock?

The current price of ImmunityBio, Inc. - Common Stock is 2.080

When was ImmunityBio, Inc. - Common Stock last traded?

The last trade of ImmunityBio, Inc. - Common Stock was at 11/14/25 04:00 PM ET

What is the market capitalization of ImmunityBio, Inc. - Common Stock?

The market capitalization of ImmunityBio, Inc. - Common Stock is 813.61M

How many shares of ImmunityBio, Inc. - Common Stock are outstanding?

ImmunityBio, Inc. - Common Stock has 814M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.